JUL 2 4 2001 **CA**MORMAPIE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Ö**Applicants Serial No.

Filed

S PATENT AND TRADEMARK OFFICE

Simons et al.
09/145,916
September 2, 1998
"STIMULATION OF ANGIOGENESIS VIANGED ENDOTHELIAL EXPRESSIONS" For

ENHANCED ENDOTHELIAL EXPRESSIOR

OF SYNDECAN-4 CORE PROTEINS"

Examiner David Guzo

Group Art Unit 1636 Attorney's Docket No. **BIS-039** 

\*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C.

20231 \_

Attorney for Applicants: (/

Signature:

\*

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed April 2, 2001, as extended through August 2, 2001, please find enclosed the following documents for filing on behalf of applicants and for formal entry into the above-identified application:

- 1. A third paper form copy of the "Sequence Listing" to be formally entered into the original Specification of the above-identified patent application.
- 2. A Third Amendment Of Specification And Request For Entry Of A Paper Form Copy Of The Sequence Listing Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.
- 3. A third computer readable form (CRF) copy of the "Sequence Listing".
- 4. A Third Statement And Verification Of Substantive Identity
  Between The Computer Readable Form (CRF) Copy And The Paper
  Form Copy Of The "Sequence Listing".
  - 5. One copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures as mailed April 2, 2001.

Respectfully submitted,

SIMONS et al.

P.O. Box 5387

Magnolia, Massachusetts 01930

Tel.: (978) 525-3794

David Prashker

Reg. No. 29,693

Attorney for applicants

plicants 'Copy

Application No.

09/1459/69

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING MUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does ont comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

	8
1. This application clearly fails to comply with the requirements of	37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulations, published May 15, 1990 and at 55 FR 18230, May 1, 1990.	at 1114 OG 29,
2. This application does not contain, as a separate part of the discouper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	losure on
paper copi, a regioner results as required by 5, circ indirect.	
3. A copy of the "Sequence Listing" in computer readable form has no submitted as required by 37 CFR 1.821(e).	t been
	•
4. A copy of the "Sequence Listing" in computer readable form has be	en submitted.
However, the content of the computer readable form does not comply with the of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the market Sequence Listing."	
5. The computer readable form that has been filed with this applicat	ion has been
found to be damaged and/or unreadable as indicated on the attached CRF Disks Report. A substitute computer readable form must be submitted as required 1.825(d).	ette Problem by 37 CFR
	·
6. The paper copy of the "Sequence Listing" is not the same as the c	omputer
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).	
7.	
Other:	
Applicant must provide:	<b>€</b>
An initial or substitute computer readable form (CRF) copy of the "Se	quence
Listing"	
An initial or substitute paper copy of the "Sequence Listing", as wel	l as an
amendment directing its entry into the specification	
A statement that the content of the paper and computer readable copie	s are the same

For questions regarding compliance with these requirements, please contact:

and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400

1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)